Clinical Trial Update: Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating a subcutaneous depot formulation of leuprolide acetate for prostate cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Leuprolide acetate depot formulation (leuprolide acetate)

Snippet

Sponsor: Camurus AB | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-02-06